ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.434,62
-0,94%
S&P 500
5.267,20
-0,31%
Dow Jones
38.544,56
-0,07%
Euro vs US Dollar
1,08789
-0,25%
Bitcoin
69.811,17
1,46%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Calliditas Therapeutics AB (CALT)

  7. Calliditas Therapeutics AB (CALT) News

CALT

Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics AB
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CALT
DatumZeitQuelleÜberschriftSymbolFirma
30/05/202422h52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
30/05/202420h20PR Newswire (US)Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyNASDAQ:CALTCalliditas Therapeutics AB
30/05/202420h18PR Newswire (US)Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyNASDAQ:CALTCalliditas Therapeutics AB
28/05/202414h46PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202414h36PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202414h28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
28/05/202414h09Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CALTCalliditas Therapeutics AB
28/05/202409h17PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
28/05/202409h14PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
23/05/202422h19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
23/05/202407h55PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
23/05/202407h52PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
16/05/202422h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
16/05/202408h45PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
16/05/202408h43PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
15/05/202414h30PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202414h24PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202413h36PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
15/05/202413h30PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
14/05/202413h52PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
14/05/202413h35PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
06/05/202408h16PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
06/05/202408h11PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
24/04/202419h35PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
24/04/202419h26PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
24/04/202409h30PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
24/04/202409h26PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
18/04/202413h13PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
18/04/202413h10PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
09/04/202413h24PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
 Showing the most relevant articles for your search:NASDAQ:CALT

Kürzlich von Ihnen besucht

AMEX
XLV
Health Care Select Sector
PM
XAUUSD
Gold vs US Dollar
NASDAQ
AMZN
Amazon.com
TG
ALV
Allianz
DBI
TDXP
Tec DAX
TG
NOV
Novo Nordisk
TG
BAS
BASF
TG
D7G
Nel ASA
TG
CBK
Commerzbank
AMEX
XLF
Financial Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
TG
BAYN
Bayer
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten